KR102403660B1 - CLEVER-1, TNF-α 및 HLA-DR 결합제를 사용하는 면역 활성화의 진단 - Google Patents

CLEVER-1, TNF-α 및 HLA-DR 결합제를 사용하는 면역 활성화의 진단 Download PDF

Info

Publication number
KR102403660B1
KR102403660B1 KR1020187028561A KR20187028561A KR102403660B1 KR 102403660 B1 KR102403660 B1 KR 102403660B1 KR 1020187028561 A KR1020187028561 A KR 1020187028561A KR 20187028561 A KR20187028561 A KR 20187028561A KR 102403660 B1 KR102403660 B1 KR 102403660B1
Authority
KR
South Korea
Prior art keywords
macrophages
clever
gly
cys
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187028561A
Other languages
English (en)
Korean (ko)
Other versions
KR20180133854A (ko
Inventor
마이자-리나 홀멘
미로 비타라
마르쿠 잘카넨
미카엘 마크시모우
Original Assignee
파론 파머수티컬스 오와이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 파론 파머수티컬스 오와이 filed Critical 파론 파머수티컬스 오와이
Publication of KR20180133854A publication Critical patent/KR20180133854A/ko
Application granted granted Critical
Publication of KR102403660B1 publication Critical patent/KR102403660B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7151—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF]; for lymphotoxin [LT]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
KR1020187028561A 2016-04-18 2017-04-18 CLEVER-1, TNF-α 및 HLA-DR 결합제를 사용하는 면역 활성화의 진단 Active KR102403660B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20165336 2016-04-18
FI20165336 2016-04-18
PCT/FI2017/050286 WO2017182706A1 (en) 2016-04-18 2017-04-18 Diagnosis of immune_activation using clever-1, tnf-alpha and hla-dr binding agents

Publications (2)

Publication Number Publication Date
KR20180133854A KR20180133854A (ko) 2018-12-17
KR102403660B1 true KR102403660B1 (ko) 2022-05-30

Family

ID=58692521

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187028561A Active KR102403660B1 (ko) 2016-04-18 2017-04-18 CLEVER-1, TNF-α 및 HLA-DR 결합제를 사용하는 면역 활성화의 진단

Country Status (10)

Country Link
US (1) US10884000B2 (enExample)
EP (1) EP3445786B1 (enExample)
JP (2) JP7100588B2 (enExample)
KR (1) KR102403660B1 (enExample)
CN (1) CN109153720B (enExample)
AU (1) AU2017252344B2 (enExample)
BR (1) BR112018070350A2 (enExample)
CA (1) CA3020418A1 (enExample)
EA (1) EA201892313A1 (enExample)
WO (1) WO2017182706A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3113895A1 (en) 2018-11-01 2020-05-07 Faron Pharmaceuticals Oy Tlr9 agonists for use in downregulating clever-1 expression on alternatively activated macrophages
US20220404366A1 (en) * 2019-11-11 2022-12-22 Faron Pharmaceuticals Oy Anti-clever-1 agents for controlling the expression of cell surface markers on leucocytes, and using these to guide anti-clever-1 based cancer treatment
CA3174858A1 (en) * 2020-04-20 2021-10-28 Juho JALKANEN Treatment of diseases with clever-1 inhibition in combination with an interleukin inhibitor
US20220227858A1 (en) 2021-01-18 2022-07-21 Faron Pharmaceuticals Oy Controlling of immune activation by soluble clever-1
WO2023105118A1 (en) * 2021-12-07 2023-06-15 Faron Pharmaceuticals Oy Method for using inflammatory markers to guide anti-clever-1 cancer treatment

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010122217A1 (en) 2009-04-22 2010-10-28 Faron Pharmaceuticals Oy A novel cell and therapeutical and diagnostical methods based thereon

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003057130A2 (en) * 2002-01-09 2003-07-17 Sirpa Jalkanen Common lymphatic endothelial and vascular endothelial receptor-1 (clever-1) and uses thereof
CN104936983A (zh) 2012-11-09 2015-09-23 特朗斯吉有限公司 对单核细胞或其前体分化的调节
BR112015032690B1 (pt) 2013-06-25 2020-03-10 Vaccinex, Inc. Uso de moléculas inibidoras de semaforina-4d em combinação com uma terapia imunomoduladora para inibir o crescimento tumoral e metástase

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010122217A1 (en) 2009-04-22 2010-10-28 Faron Pharmaceuticals Oy A novel cell and therapeutical and diagnostical methods based thereon
JP2012524536A (ja) 2009-04-22 2012-10-18 ファロン ファーマシューティカルズ オサケ ユキチュア 新規細胞ならびに該細胞にもとづく治療および診断方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Palani S. et al, J Immunol 196:pp.115~123 (2015.11.25.)*

Also Published As

Publication number Publication date
JP7100588B2 (ja) 2022-07-13
AU2017252344B2 (en) 2023-12-21
WO2017182706A1 (en) 2017-10-26
EP3445786B1 (en) 2023-10-04
US10884000B2 (en) 2021-01-05
JP7302049B2 (ja) 2023-07-03
US20190064180A1 (en) 2019-02-28
CN109153720A (zh) 2019-01-04
KR20180133854A (ko) 2018-12-17
JP2019521312A (ja) 2019-07-25
AU2017252344A1 (en) 2018-10-11
EA201892313A1 (ru) 2019-03-29
CA3020418A1 (en) 2017-10-26
BR112018070350A2 (pt) 2019-01-29
EP3445786C0 (en) 2023-10-04
CN109153720B (zh) 2022-10-21
JP2022065088A (ja) 2022-04-26
EP3445786A1 (en) 2019-02-27

Similar Documents

Publication Publication Date Title
JP7302049B2 (ja) Ｃｌｅｖｅｒ－１、ｔｎｆ－アルファおよびｈｌａ－ｄｒ結合剤を用いた免疫活性化の診断
JP7366091B2 (ja) Ｍｖａ又はｍｖａδｅ３ｌの固形腫瘍免疫療法剤としての使用
JP7529754B2 (ja) がんを処置するための方法および組成物
CN112567026B (zh) Il-31改善用于癌症的基于巨噬细胞的过继性细胞疗法的功效
TWI847958B (zh) 用精胺酸耗盡劑進行之組合癌症免疫療法
Hervas-Stubbs et al. Conventional but Not Plasmacytoid Dendritic Cells Foster the Systemic Virus–Induced Type I IFN Response Needed for Efficient CD8 T Cell Priming
Lang et al. Tumor immune escape mechanisms: impact of the neuroendocrine system
WO2023056972A1 (zh) 戈氏梭菌联合肿瘤血管生成抑制剂的应用
HK1261998B (en) Diagnosis of immune activation using clever-1, tnf-alpha and hla-dr binding agents
HK1261998A1 (en) Diagnosis of immune activation using clever-1, tnf-alpha and hla-dr binding agents
US20160030558A1 (en) Enhancement of vaccines
EP4285913A1 (en) Highly effective adoptive t cell therapy
Manjarres et al. Microbiota-dependent T-cell response to α-synuclein-derived antigens triggers the development of hypersensitivity and neuroinflammation associated with Parkinson's Disease
WO2018088933A1 (en) Anti-tumor effects of a viral vector encoding a toll-like receptor and a toll-like receptor agonist
Jung et al. Synergistic Effect of Tolerogenic Dendritic Cells and Etanercept on a Collagen-induced Arthritis Animal Model
WO2022032592A1 (en) Interleukin-17d and cd93 as a new cytokine-receptor pair in the immune system
HK40088320A (zh) Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用
BG66049B1 (bg) Средство за конкурентно инхибиране и/или блокиране на карциноембрионалния антиген /сеа/
EA043588B1 (ru) Лекарственное средство, содержащее рекомбинантные лектины омелы, для лечения опухолей головного мозга
HK1252730B (en) Use of mva or mvadeltae3l as immunotherapeutic agents against solid tumors

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20181002

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200130

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210902

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220328

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220525

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220526

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20250428

Start annual number: 4

End annual number: 4